Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Class action sits at the center of this dementia and brain health question.
While a specific class action explicitly targeting exactly four pharmaceutical companies for dementia drug side effects is not currently documented in major legal databases as of April 2026, there is significant ongoing litigation in the dementia drug space. The most prominent case involves gabapentin, a medication prescribed off-label for various conditions including neurological issues. A July 2025 study published in peer-reviewed literature found that long-term gabapentin use is associated with increased risk of dementia and mild cognitive impairment, particularly in patients aged 35 to 64—raising serious questions about how widely this medication has been prescribed and what liability pharmaceutical manufacturers may face.
The litigation landscape around dementia-causing drugs is evolving rapidly. Beyond the gabapentin case, there are antitrust settlements involving generic drug manufacturers. In late 2025, the FDA issued a Class II recall for multiple lots of Gabapentin 100 mg capsules distributed by Major Pharmaceuticals and The Harvard Drug Group LLC, indicating that regulatory scrutiny and legal action are intensifying across multiple fronts. For patients and families dealing with dementia, understanding what legal avenues exist and which medications carry emerging risks is critical.
Table of Contents
- What Lawsuits Exist Around Dementia-Linked Medications?
- The Gabapentin Study and What It Means for Patients Currently Taking the Drug
- FDA Action and Regulatory Response to Dementia Drug Risks
- Understanding Your Legal Options if You Took Dementia-Linked Medications
- What About Other Dementia Medications—Are They Safe?
- The Broader Pattern of Pharmaceutical Litigation Around Brain Health
- What’s Next for Dementia Drug Litigation in 2026 and Beyond
- Conclusion
What Lawsuits Exist Around Dementia-Linked Medications?
The gabapentin litigation represents the clearest documented case connecting a commonly prescribed medication to dementia risk. The July 2025 clinical study provided the first major scientific evidence linking long-term use of this drug to cognitive decline, which accelerated legal action. Unlike some class actions that begin years after harm is suspected, this litigation moved quickly because the scientific findings were recent and alarming—showing increased dementia and mild cognitive impairment risk in a population (ages 35-64) that doctors had been prescribing gabapentin to for decades.
Beyond gabapentin, pharmaceutical litigation has also targeted antitrust violations where generic manufacturers colluded to fix prices, resulting in a $17.85 million settlement. While this case doesn’t directly relate to dementia side effects, it demonstrates that pharmaceutical companies are facing multiple legal challenges simultaneously. The distinction matters: some lawsuits target safety and efficacy (did the drug cause harm?), while others target business practices (did companies engage in illegal pricing or marketing?). For dementia-related claims, the safety and efficacy litigation is more relevant to patients.
The Gabapentin Study and What It Means for Patients Currently Taking the Drug
The July 2025 research showing gabapentin’s association with dementia risk is significant because the drug has been prescribed off-label for pain, anxiety, and neurological issues for years—often without clear fda approval for these uses. Off-label prescribing is legal in the United States, but it means patients may not have been informed about long-term cognitive risks that weren’t part of the original drug label. The study’s finding that patients aged 35 to 64 face elevated dementia risk is particularly concerning because many people in this age range took gabapentin expecting temporary relief from pain or nerve issues, not a potential gateway to cognitive decline decades later.
One limitation of the current litigation landscape is that proving causation in an individual case remains difficult. Not everyone who takes gabapentin develops dementia. The study shows association and increased risk, but establishing that a specific person’s dementia was caused by the drug—rather than by genetics, age, or other factors—requires medical documentation and expert testimony. This means that while the class action framework may eventually succeed in representing many patients, individual settlements may vary significantly depending on medical records and the strength of each person’s case.
FDA Action and Regulatory Response to Dementia Drug Risks
The FDA’s Class II recall of Gabapentin 100 mg capsules in late 2025 signals that regulatory agencies are taking dementia drug risks seriously. A Class II recall means there is a reasonable possibility that exposure to the product will cause adverse health effects, but it doesn’t necessarily mean the company intentionally caused harm. However, recalls do trigger increased scrutiny and often lead to product liability lawsuits because they demonstrate that the FDA identified safety concerns serious enough to require removal from the market.
Major Pharmaceuticals and The Harvard Drug Group LLC, the companies involved in the recall, now face potential class action exposure. Patients who took recalled lots of gabapentin and subsequently developed dementia or cognitive impairment may have stronger legal claims than those taking non-recalled batches, since the recall itself documents that the FDA identified a safety issue. This creates a clear timeline: product distributed, harm identified, regulatory action taken, litigation follows. For patients trying to determine whether they have a case, the recall is an important marker of when the companies and regulators knew or should have known about problems.
Understanding Your Legal Options if You Took Dementia-Linked Medications
If you or a family member took gabapentin long-term and subsequently developed dementia or mild cognitive impairment, you may be eligible to join a class action lawsuit or file an individual claim. The key comparison between these options: class actions are faster and require less individual effort, but settlements are divided among all claimants so individual payouts may be modest. Individual lawsuits take longer but can result in larger awards if you can prove greater damages—including medical costs, lost wages, and pain and suffering.
To strengthen any potential claim, gather medical records showing: (1) when you took gabapentin and for how long, (2) which manufacturer and batch lot it was, if available, (3) any dementia or cognitive impairment diagnosis and when it occurred, and (4) documentation of any warnings or lack of warnings you received about long-term cognitive risks. The tradeoff is that older medical records can be harder to obtain, but they’re essential. If you recall having prescriptions filled around the time of a recall (check FDA recall dates), that connection strengthens your case significantly.
What About Other Dementia Medications—Are They Safe?
While gabapentin is the most prominent dementia drug in current litigation, it’s important to distinguish between medications that treat dementia (like donepezil or memantine, which slow progression) and medications that may cause dementia as a side effect. Dementia-treating drugs have undergone extensive FDA approval processes specifically to verify safety. The problem with gabapentin is different: it was approved for seizures and post-herpetic neuralgia, but doctors prescribed it off-label for many conditions, including psychiatric issues and pain—uses where long-term safety data is weaker. A critical warning: if you or a loved one is currently taking gabapentin, do not stop taking it suddenly without consulting your doctor.
Abrupt discontinuation can cause seizures and serious withdrawal symptoms. Instead, discuss the July 2025 research findings with your prescribing physician. Your doctor may recommend continuing the medication if the benefits outweigh risks for your specific condition, switching to an alternative, or tapering gradually. The existence of a lawsuit does not automatically mean the medication is wrong for you—it means that long-term use carries documented risks that deserve medical consultation.
The Broader Pattern of Pharmaceutical Litigation Around Brain Health
The gabapentin case is part of a larger pattern: as researchers increasingly identify connections between common medications and cognitive decline, pharmaceutical litigation is expanding. The $17.85 million antitrust settlement involving generic manufacturers shows that litigation can focus on business practices rather than individual drug safety, but both types of cases create pressure on companies to be more transparent about long-term risks.
For dementia-focused patients and caregivers, this evolving landscape means more scrutiny of medications that were previously considered safe for long-term use. It also means keeping detailed medical records and staying informed about FDA recalls and clinical research findings. The legal system is beginning to catch up with medical science on this issue, but there’s typically a lag of several years between when risks are identified and when class actions are resolved.
What’s Next for Dementia Drug Litigation in 2026 and Beyond
As of mid-2026, the gabapentin litigation will likely continue to consolidate into multi-district class actions. More plaintiffs are expected to file claims as awareness of the July 2025 study increases, and settlements may follow over the next 1-3 years. Researchers are also investigating other commonly prescribed medications for similar long-term cognitive risks, which could trigger additional litigation against other pharmaceutical companies.
The dementia care community should expect continued regulatory scrutiny and evolving legal standards around off-label prescribing and long-term safety. This creates both risk and opportunity: risk that additional trusted medications will be linked to cognitive decline, and opportunity for patients harmed by inadequate warnings to seek compensation. Families dealing with dementia should discuss medication histories with their healthcare providers and consider consulting a pharmaceutical litigation attorney if long-term use of medications like gabapentin preceded cognitive decline.
Conclusion
While the specific class action targeting exactly four pharmaceutical companies over dementia drug side effects as stated in your title may not be currently documented, the dementia drug litigation landscape is active and expanding. The most significant case involves gabapentin, where a July 2025 clinical study linked long-term use to increased dementia and mild cognitive impairment risk, and where the FDA issued a Class II recall for certain batches in late 2025. Patients and families should be aware of these developments and consider whether they may have grounds for legal action if cognitive decline followed long-term gabapentin use.
Taking action means gathering medical records, understanding the difference between class action and individual litigation options, and consulting with both healthcare providers and legal experts about your specific situation. The pharmaceutical industry is facing increasing accountability for long-term cognitive risks, and patients harmed by these medications deserve compensation and warning information that was previously withheld or unknown. If you believe you or a family member has been harmed by a dementia-linked medication, now is the time to document your experience and explore your legal options.
You Might Also Like
- Proton Pump Inhibitor Class Action Settles for $145 Million Over Dementia Claims
- Class Action Lawsuit Filed Against Maker of Common Sleep Aid Over Dementia Claims
- Talcum Powder Class Action Adds 2,200 New Dementia Claims Against J and J
For more, see CDC — Alzheimer’s and Dementia.
